Positron emission tomography using rIKFJ2fluoro-2-deoxY-D-glucose was performed in nine chronic schizophrenic patients both when medication-free and when medicated with neuroleptics. To tal brain cortex. temporal cortex, and basal ganglia glucose use was sig-PET scans of medication-free chronic schizo-
Several recent reports of studies using positron emission tomography (PET) describe altered brain metabolic activity in schizophrenic patients com pared with normal controls (Farkas et aI. , 1980; Widen et aI. , 198 I; Buchsbaum et aI. , 1982 Buchsbaum et aI. , , 1984 . These alterations consist of decreased anterior/pos terior cortical metabolic gradients and increased temporal cortical activity. Most of these studies have used [ 18 F]2-fluoro-2-deoxY-D-glucose (FDG) as the tracer compound, which will be taken up selectively by cells using glucose metabolism for energy. Deoxyglucose uptake appears to be directly correlated with regional blood flow (Kuschinsky et aI. , 1981) . Thus, the PET studies have been consis tent with previous reports of a relative decrease in frontal compared with posterior blood flow, as well as increased temporal/parietal blood flow in chronic schizophrenic patients (lngvar and Franzen, 1974a,b) .
We recently reported the presence of decreased anterior/posterior cortical metabolic gradients in phrenic patients compared with controls (Buchs baum et al. . 1984) . This abnormal pattern did not appear either to be specific to schizophrenia or to correlate with characteristic symptoms of schizo phrenia and the overall psychopathology (DeLisi et aI. , 1985a) . We have also reported a bilateral in crease in glucose metabolism in temporal lobes of medication-free schizophrenic patients that was greater on the left than on the right (DeLisi et aI. , 1985b) . In all our studies, the unmedicated patients were withdrawn from a variety of neuroleptics for 14-150 days, but there was no correlation between the number of days off medication and the meta bolic measurements.
The present study determines how anterior/pos terior metabolic gradients and temporal cortex, basal ganglia, and overall metabolic activity change with pharmacologic and psychiatric state. We hy pothesized that if the abnormalities previously re ported are related to the manifestation of psychotic symptoms, then antipsychotic medication and im provement in mental status should be accompanied by normalization of anterior/posterior gradients and a decrease in temporal lobe activity. Changes in basal ganglia activity associated with medication should also be seen as the basal ganglia are rich in dopaminergic receptors, and the clinical potency of neuroleptics appears to be directly related to their ability to block dopamine receptors (Carlsson, 
METHODS
Nine DSM-III diagnosed chronic schizophrenic pa tients (18-33 years of age, mean ± SD 26 ± 5 years; 6 males, 3 females) had two PE T studies completed ac cording to the methods previously described (Buchsbaum et aI., 1982 (Buchsbaum et aI., , 1984 . These patients were a subgroup of the patients previously described in reports, who were avail able and consented to a second scan (Buchsbaum et aI., 1984; DeLisi et aI., 1984a) . They had a mean (± SD) length of illness of 7 ± 3.9 years prior to the first scan. Three were outpatients during the time of both scans, five were hospitalized on National Institute of Mental Health research units during both scans, and one was initially hospitalized in the medication-free state, but an outpa tient when medicated. They all exhibited a range of psy chopathology, as described in DeLisi et al. (l985a) . Normal control subjects for comparison were also those described in the previous reports and consisted of healthy, age-and gender-matched normal volunteers. All conditions for the procedure were standardized within individuals, and scan slices were matched to obtain iden tical levels for each slice obtained. Time between scans varied from 3 to 32 months (mean ± SD 11.2 ± 8 months). All patients were first scanned during the med ication-free period, then stabilized on a clinical dose of a neuroleptic titrated to produce a maximum clinical re sponse. Four patients were medicated with tluphenazine (two at 20 mg, two at 40 mg), two with haloperidol (10 and 30 mg), one with chlorpromazine (200 mg), one with thioridizine (300 mg), and one with loxapine (50 mg). The patients were medicated from 36 days to 32 months (mean 7.4 months) prior to the second scan.
The brief psychiatric rating scale (Overall and Gorham, 1963) was scored for each patient during each scan by the same psychiatrist who had no knowledge of the scan re sults at the time of the ratings.
The subjects sat in an acoustically treated darkened room with eyes closed. After injection of FDG, the sub jects remained in the room for 30-40 min, during which time serial arteriolized venous blood samples were taken from the left arm for quantification of FDG uptake. Fol lowing the uptake period, seven to eight scan slices were completed at 13-mm intervals from � 104 to 18 mm above the canthomeatal line using an Ortec EeAT II scanner. Scans were performed with median-resolution shadow shields, scan mode, and reconstruction filter. Resolution was 1.75 cm full width half-maximum in plane and 1.78 cm in the axial direction. A calculated attenuation cor rection was used for all studies, based on an ellipse po sitioned around the perimeter of the head. The machine was calibrated every day a scan was done using a uniform 20-cm cylindrical phantom with 18F and compared with well counter data. Scan duration for each slice was ad justed so that each image contained at least 600,000 counts, and slices were usually obtained within 10-15 min, the total scan time being 1.5 h.
Values of glucose use were calculated according to the Sokoloff et al. (1977) model, using an adaption of a pro gram developed by Sokoloff. Rate constants and the lumped constant from Phelps et al. (1979) were entered. Each pixel of each slice was converted from raw counts to glucose use in micromolesll 00 g tissue/minute and stored. For each area of interest, the mean glucose use was calculated as the sum of pixel values per number of pixels contained in the outline. 1985 For the purpose of quantifying a mean cortical activity and obtaining anterior/posterior gradients, the second to third slice was used, or a slice that was �80 mm above the canthomeatal line. This is the lowest slice above the lateral ventricles that clearly shows the centrum se miovale and has the largest cortical rim. It previously was found to be the slice showing the largest differences be tween schizophrenic patients and controls (Buchsbaum et aI., 1982) . The anterior/posterior gradients were deter mined using the cortical peel computer analyses previ ously described (Buchsbaum et aI., 1982 (Buchsbaum et aI., , 1984 and ob taining eight cortical sectors corresponding to left and right top, middle, and posterior portions of the cortical rim. A ratio was then calculated of the right plus left top sectors to the right plus left posterior sectors.
Maximum temporal lobe activity was quantified using the lowest slice (�18-20 mm above the canthomeatal line). This slice is the one that best delineates the tem poral lobes from other cerebral areas and was used for previously reported analyses of temporal lobe activity in schizophrenic patients (DeLisi et aI., 1985b) . For this analysis, a program using a boundary-finding algorithm (Buchsbaum et aI., 1983 ) was used to outline each tem poral lobe. The lobe margin threshold was selected as the lowest glucose metabolic rate with which a boundary sur rounding the temporal lobe could be formed, lower values forming an outline that also included the frontal lobe. Within the outline, the mean and the maximum glucose values were calculated. Left/right ratios were also deter mined.
Basal ganglia activity was quantified by visually placing a 5 x 5 pixel (1 pixel = 0.28 cm or 2.8 cm3 voxel volume) box under both left and right lateral ventricles in the re gion of the caudate nucleus, as depicted in similar slices in a standard anatomical atlas (Matsui and Hirano, 1978) , and using a computer program to calculate the mean ac tivity in each box. Te mporal lobe and basal ganglia activ ities were expressed as micromoles per \00 g brain tissue per minute, as well as per mean cortical activity of the slice used.
RESULTS
Mean cortical glucose use was significantly in creased following neuroleptic treatment (paired t test, t = 2.6, p < 0.02) (see Fig. 1 ).
There was no significant change in anterior/pos terior gradients following neuroleptic treatment (means 1.04 and 1.00; a decrease in six of nine pa tients; t = 0.82) from the medication-free to the medicated state (see Fig. 2 ).
Glucose use in left and right temporal lobes is shown in Ta ble 1 for the patients and controls from our previous study (DeLisi et aI. , 1985b) . While ab solute glucose activity was significantly increased in the patients relative to controls, there also was a further increase in patients in the medicated relative to the nonmedicated state, particularly in the left temporal lobe (paired t test, t = 3.5, p < 0.01).
Mean absolute glucose use as well as the ratio of mean caudate glucose use to mean whole-cortex ac tivity in the caudate nucleus was increased bilat- (21.6 ± 5.5 vs. 26.5 ± 6.5; two-tailed paired t test, t = 2.6, P < 0.02). The mean cortical glucose use for nine normal con trols matched for age, gender, and time period of scan was 24.5 ± 7.3 and 28.6 ± 5.1.
erally in the medicated relative to the nonmedicated state. There was no significant difference in caudate activity between patients in the medication-free state and controls. The medicated patients, how ever, had significantly greater mean bilateral cau date glucose use per slice than controls (see Ta ble 2). Three of the nine patients did not show improve ment in total brief psychiatric rating scale scores, or in separate items of the scale, on medication. Of the six who improved clinically with neuroleptic medication, five showed decreases in anterior/pos terior gradients on medication, while one of the three nonimprovers also had a decreased gradient on medication. No clinical state changes, as mea sured by the brief psychiatric rating scale, corre lated with the changes in anterior/posterior gra dients or total cortical, temporal lobe, or caudate glucose use (Pearson and Spearman coefficients were nonsignificant).
Since all subjects were scanned first in the med ication-free period and then on medication, with the scans taking place over a period of -3 years, changes in overall glucose activity relative to the time of scan were investigated. There was no sig-nificant difference in absolute glucose metabolism for nine normal subjects scanned in other studies at the same time as the medication-free schizophrenic patients versus age-and gender-matched normal subjects scanned at similar times to the patients when medicated (mean ± SD,24.S ± 7.3 vs. 28.6 ± 5. 1 j..L M/IOO g/min).
DISCUSSION
The present PET study of nine schizophrenic pa tients both on and off neuroleptic medication finds significant changes in several variables of regional glucose use. The frontal/occipital (or anterior/pos terior) gradient, found by several investigators to be decreased in schizophrenic patients, was found to decrease even further from the medication-free state to the medicated state in six of the nine pa tients, although this difference could have been reached entirely by chance. Overall cortical meta bolic activity increased in all but one patient on medication. Te mporal lobe glucose use relative to other cortical areas did not change significantly, al though absolute glucose use in the left temporal lobe was greater in the medicated state. In addition, both absolute and relative activity in the caudate nucleus were also increased in the medicated state. An increase in absolute metabolic activity in tem poral lobes and caudates in patients on medication is consistent with the overall increase in cortical activity observed, although the increase in caudate relative to whole-slice glucose use may be related to specific dopamine receptor blocking effects of neuroleptics, since these receptors are heavily con centrated in the caudate. The biochemical mecha nisms for these associations, however, remain un clear.
The findings of reduced anterior/posterior gra dients, increased brain glucose consumption, and increased temporal/parietal activity in blood flow and PET studies have been associated with schizo phrenia and other related psychiatric disorders. That we find even further deviation from normal for these measures with neuroleptic medication, re gardless of improvement in mental status, suggests that these differences are not directly related to psy chiatric symptomatology. In general, studies re porting the above differences between patients and controls have used chronically ill subjects with long previous histories of pharmacologic treatment, de spite withdrawal from medication for a few weeks prior to the PET studies. We do not know whether drug holidays of greater duration would promote a normalization of cerebral glucose metabolic rates. Although we found no correlation of our measures with time withdrawn from medication (Buchsbaum et al. , 1984) , the effects of long-term medication after withdrawal may vary among individuals. If these alterations are found to be present in schizo phrenic patients prior to neuroleptic exposure at the onset of their disorder, this important issue would be clarified. One recent study using oxygen utili zation and PET failed to find evidence of hypofron tality or altered basal ganglia activity in predomi nantly unmedicated, first-episode schizophrenic pa tients, although some abnormalities in hemispheric laterality were found (Sheppard et al., 1983) .
In addition, our study may also be confounded by an order effect in study design, since unpub lished data from our group show an order effect with respect to somatosensory evoked potentials. All subjects in the present study were scanned first in the medication-free state and then in the medi- cated state. Moreover, although there were no known changes in our PET methodology in the pe riod of time between studies, it is puzzling that we found a nonsignificant trend for glucose consump tion to increase from our earlier time period to the later. We cannot eliminate the possibility that the statistically significant increase in cortical glucose use for our patients when medicated was an artifact of the numerous technical difficulties inherent in the PET procedure and their refinement over time (see Hoffman et aI. , 1984; Mazziotta and Phelps, 1984) .
Although the present study suggests that neuro leptic medication may directly or indirectly increase overall brain metabolic activity, we do not have similar data on intrasubject variation with time for unmedicated individuals or those undergoing a change in psychiatric state but not medication. Phelps et al. (1979) , however, report a ± 12% vari ation in absolute glucose activity with time for the same individual; in our study, the nine subjects ex hibited a 32% mean change in metabolic activity.
Our findings are. for the most part. contrary to the animal data of McCulloch et al. (1982) , who observed a significant decline in cerebral glucose metabolic activity in the majority of 43 anatomically discrete regions of rat brain after intravenous halo peridol administration. It is of interest. however. that the nucleus accumbens. a structure anatomi cally and functionally associated with the caudate nucleus. and the pars compacta of the substantia nigra showed increased glucose utilization fol lowing haloperidol administration. despite the overall reduced brain activity. In addition. the acute effects of neuroleptics may not be comparable with the chronic effects of these agents, and may. in fact. be opposite. as has been shown in some animal studies (White and Wang, 1983) .
Although our data are also opposite to the changes noted by Nilsson et al. (1977) in cerebral blood flow studies of I I patients before and after haloperidol treatment. they are consistent with a recent PET study by Brodie et al. (1984) finding a 25% increase in mean glucose rates in six chronic schizophrenic patients after thiothixene treatment.
It is also possible that different classes of neu roleptics have different effects on brain glucose use, thus confounding our results. Since the patients in our study were not on a research treatment pro tocol, we were not able to control the choice of neuroleptic used for clinical response by the treating physician. We did not, however, notice any changes in our measures characteristic of the four patients given fluphenazine versus the two given haloperidol, or the total patients on phenothiazines (six) versus the other classes of neuroleptics (three).
The lack of difference in caudate glucose use in the medication-free patients compared with con trols and the significant difference in these same patients when medicated fail to provide evidence for an abnormality in central dopaminergic activity in schizophrenia, but confirm the effect of neuro leptics on this system. These data, however, do not rule out the dopamine hypothesis of schizophrenia, since the use of FDG to trace metabolic activity does not determine activity in cells producing se lective neurotransmitters, but rather reflects the complex activity of multiple neurotransmitter in teractions. In future studies, using a ligand specific for only one type of receptor [such as the use of spiroperidol to label the dopamine receptor (Wagner et aI. , 1983 )], we may be able to determine which activity is more relevant to the psychopa thology of schizophrenia and its therapy.
